Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 6/20 | 0.47 |
| ▸ | PLA2G4A | P47712 | 6/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22076978 | 0.90 | ADH5 (0.45) | TBXAS1PLA2G4ACYP11B1CYP11B2FFAR1 | |
| SCHEMBL22078068 | 0.89 | TBXAS1 (0.50) | TBXAS1PLA2G4A | |
| SCHEMBL22076963 | 0.88 | TBXAS1 (0.49) | TBXAS1PLA2G4A | |
| SCHEMBL22076995 | 0.86 | TBXAS1 (0.47) | TBXAS1PLA2G4AMAOBMAPT | |
| SCHEMBL22078066 | 0.85 | USP14 (0.49) | TBXAS1PLA2G4ACYP11B1CYP11B2FFAR1 | |
| SCHEMBL25492042 | 0.84 | CYP11B1 (0.43) | CYP11B1CYP11B2MAOAMAOBALDH1A1 | |
| SCHEMBL22078076 | 0.83 | TBXAS1 (0.53) | TBXAS1PLA2G4AALDH1A1HPGDMAPT | |
| SCHEMBL22077233 | 0.79 | ADH5 (0.61) | TBXAS1PLA2G4AMAOBMAPT | |
| SCHEMBL25493548 | 0.79 | ADH5 (0.45) | TBXAS1PLA2G4AMAOBALDH1A1SMN1; SMN2 | |
| SCHEMBL22076992 | 0.78 | USP14 (0.44) | TBXAS1PLA2G4AFFAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655244-B2 | Carbazole compounds and methods of use thereof | GSNO THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20200181129-A1 | CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF | GSNO THERAPEUTICS, INC. | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655244-B2 | Carbazole compounds and methods of use thereof | GSR, CBR3, CBR1 | TBXAS1 1031/4885PLA2G4A 2266/4885CYP11B1 15/4885 |
| US-20200181129-A1 | CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF | GSR, CBR3, CBR1 | TBXAS1 1031/4885PLA2G4A 2266/4885CYP11B1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.